NO321454B1 - Defektiv, rekombinant adenovirus inneholdende en heterolog DNA-sekvens hvis ekspresjon i en malcelle tillater i det minste partielt a inhibere celledeling, anvendelser og farmasoytisk preparat derav. - Google Patents

Defektiv, rekombinant adenovirus inneholdende en heterolog DNA-sekvens hvis ekspresjon i en malcelle tillater i det minste partielt a inhibere celledeling, anvendelser og farmasoytisk preparat derav. Download PDF

Info

Publication number: NO321454B1
Authority: NO; Norway
Prior art keywords: defective; sequence; gene; pharmaceutical preparation; adenovirus
Prior art date: 1993-04-22

Application number

NO19954132A

Other languages

English (en)

Norwegian (no)

Other versions

NO954132L (no

NO954132D0 (no

Inventor

Hedi Haddada

Michel Perricaudet

Evelyne May

Original Assignee

Aventis Pharma Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-04-22

Filing date

1995-10-17

Publication date

2006-05-15

1995-10-17 Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa

1995-10-17 Publication of NO954132L publication Critical patent/NO954132L/no

1995-10-17 Publication of NO954132D0 publication Critical patent/NO954132D0/no

2006-05-15 Publication of NO321454B1 publication Critical patent/NO321454B1/no

Links

241000701161 unidentified adenovirus Species 0.000 title claims abstract description 60
230000002950 deficient Effects 0.000 title claims abstract description 25
230000014509 gene expression Effects 0.000 title claims abstract description 24
108091028043 Nucleic acid sequence Proteins 0.000 title claims abstract description 14
239000000825 pharmaceutical preparation Substances 0.000 title claims description 16
230000032823 cell division Effects 0.000 title claims description 9
108090000623 proteins and genes Proteins 0.000 claims description 65
206010028980 Neoplasm Diseases 0.000 claims description 31
241000701022 Cytomegalovirus Species 0.000 claims description 17
238000004519 manufacturing process Methods 0.000 claims description 11
201000011510 cancer Diseases 0.000 claims description 10
230000002265 prevention Effects 0.000 claims description 8
230000002401 inhibitory effect Effects 0.000 claims description 7
230000003612 virological effect Effects 0.000 claims description 6
238000002360 preparation method Methods 0.000 claims description 4
238000002560 therapeutic procedure Methods 0.000 claims description 4
230000000259 anti-tumor effect Effects 0.000 claims description 3
108091007433 antigens Proteins 0.000 claims description 3
230000010076 replication Effects 0.000 claims description 3
239000000427 antigen Substances 0.000 claims description 2
102000036639 antigens Human genes 0.000 claims description 2
229960005486 vaccine Drugs 0.000 claims description 2
230000021616 negative regulation of cell division Effects 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 37
239000013598 vector Substances 0.000 description 16
238000000034 method Methods 0.000 description 12
108020004414 DNA Proteins 0.000 description 11
102000004169 proteins and genes Human genes 0.000 description 11
239000013612 plasmid Substances 0.000 description 9
241000700605 Viruses Species 0.000 description 7
238000010276 construction Methods 0.000 description 6
108010076504 Protein Sorting Signals Proteins 0.000 description 5
108700025716 Tumor Suppressor Genes Proteins 0.000 description 5
102000044209 Tumor Suppressor Genes Human genes 0.000 description 5
230000006801 homologous recombination Effects 0.000 description 5
238000002744 homologous recombination Methods 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
108700020796 Oncogene Proteins 0.000 description 4
230000004663 cell proliferation Effects 0.000 description 4
230000001413 cellular effect Effects 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
230000001173 tumoral effect Effects 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
102000043276 Oncogene Human genes 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
230000006378 damage Effects 0.000 description 3
239000013604 expression vector Substances 0.000 description 3
238000000605 extraction Methods 0.000 description 3
239000012634 fragment Substances 0.000 description 3
238000001415 gene therapy Methods 0.000 description 3
230000001939 inductive effect Effects 0.000 description 3
108020004999 messenger RNA Proteins 0.000 description 3
230000035772 mutation Effects 0.000 description 3
230000008488 polyadenylation Effects 0.000 description 3
108700042226 ras Genes Proteins 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
238000001890 transfection Methods 0.000 description 3
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
229920000936 Agarose Polymers 0.000 description 2
102000004594 DNA Polymerase I Human genes 0.000 description 2
108010017826 DNA Polymerase I Proteins 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
241000701533 Escherichia virus T4 Species 0.000 description 2
108700039691 Genetic Promoter Regions Proteins 0.000 description 2
241000282412 Homo Species 0.000 description 2
108091092195 Intron Proteins 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
102000007999 Nuclear Proteins Human genes 0.000 description 2
108010089610 Nuclear Proteins Proteins 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
230000004913 activation Effects 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
239000002299 complementary DNA Substances 0.000 description 2
239000012228 culture supernatant Substances 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000000694 effects Effects 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
230000028993 immune response Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000001823 molecular biology technique Methods 0.000 description 2
-1 much Proteins 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
108700025694 p53 Genes Proteins 0.000 description 2
239000002245 particle Substances 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000012546 transfer Methods 0.000 description 2
230000009466 transformation Effects 0.000 description 2
241001430294 unidentified retrovirus Species 0.000 description 2
DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
208000005623 Carcinogenesis Diseases 0.000 description 1
102000053642 Catalytic RNA Human genes 0.000 description 1
108090000994 Catalytic RNA Proteins 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
101150014889 Gad1 gene Proteins 0.000 description 1
102100035902 Glutamate decarboxylase 1 Human genes 0.000 description 1
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
102000003792 Metallothionein Human genes 0.000 description 1
108090000157 Metallothionein Proteins 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
241001494479 Pecora Species 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
108010089430 Phosphoproteins Proteins 0.000 description 1
102000007982 Phosphoproteins Human genes 0.000 description 1
102100027584 Protein c-Fos Human genes 0.000 description 1
101710090875 Protein c-Fos Proteins 0.000 description 1
108700020978 Proto-Oncogene Proteins 0.000 description 1
102000052575 Proto-Oncogene Human genes 0.000 description 1
201000000582 Retinoblastoma Diseases 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
108700025695 Suppressor Genes Proteins 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
108700005077 Viral Genes Proteins 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
230000003321 amplification Effects 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
229910052793 cadmium Inorganic materials 0.000 description 1
BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
229940022399 cancer vaccine Drugs 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
238000012761 co-transfection Methods 0.000 description 1
229940047120 colony stimulating factors Drugs 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000003831 deregulation Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
238000011049 filling Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
229910001385 heavy metal Inorganic materials 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
230000016507 interphase Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000002502 liposome Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
239000000203 mixture Substances 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
229940046166 oligodeoxynucleotide Drugs 0.000 description 1
201000008968 osteosarcoma Diseases 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
239000000047 product Substances 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
102000016914 ras Proteins Human genes 0.000 description 1
108010014186 ras Proteins Proteins 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
108091092562 ribozyme Proteins 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000010474 transient expression Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
102000003390 tumor necrosis factor Human genes 0.000 description 1
230000009452 underexpressoin Effects 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
238000012795 verification Methods 0.000 description 1
108700026220 vif Genes Proteins 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1758—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals p53
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
- C12N2710/10241—Use of virus, viral particle or viral elements as a vector
- C12N2710/10243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Virology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Epidemiology (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Wood Science & Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Microbiology (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Biophysics (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
General Chemical & Material Sciences (AREA)
Plant Pathology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Marine Sciences & Fisheries (AREA)
Physics & Mathematics (AREA)
Mycology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO19954132A 1993-04-22 1995-10-17 Defektiv, rekombinant adenovirus inneholdende en heterolog DNA-sekvens hvis ekspresjon i en malcelle tillater i det minste partielt a inhibere celledeling, anvendelser og farmasoytisk preparat derav. NO321454B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9304745A FR2704234B1 (fr)	1993-04-22	1993-04-22	Virus recombinants, preparation et utilisation en therapie genique.
PCT/FR1994/000421 WO1994024297A1 (fr)	1993-04-22	1994-04-15	Adenovirus recombinants defectifs pour la therapie genique des tumeurs

Publications (3)

Publication Number	Publication Date
NO954132L NO954132L (no)	1995-10-17
NO954132D0 NO954132D0 (no)	1995-10-17
NO321454B1 true NO321454B1 (no)	2006-05-15

Family

ID=9446321

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19954132A NO321454B1 (no)	1993-04-22	1995-10-17	Defektiv, rekombinant adenovirus inneholdende en heterolog DNA-sekvens hvis ekspresjon i en malcelle tillater i det minste partielt a inhibere celledeling, anvendelser og farmasoytisk preparat derav.

Country Status (15)

Country	Link
EP (2)	EP0695360B1 (de)
JP (1)	JPH08508879A (de)
AT (1)	ATE332386T1 (de)
AU (1)	AU696245B2 (de)
DE (1)	DE69434781T2 (de)
DK (1)	DK0695360T3 (de)
ES (1)	ES2264123T3 (de)
FI (1)	FI118011B (de)
FR (1)	FR2704234B1 (de)
HU (1)	HU220346B (de)
NO (1)	NO321454B1 (de)
NZ (1)	NZ265306A (de)
PT (1)	PT695360E (de)
WO (1)	WO1994024297A1 (de)
ZA (1)	ZA942778B (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1992015680A1 (en)	1991-03-06	1992-09-17	Board Of Regents, The University Of Texas System	Methods and compositions for the selective inhibition of gene expression
US6410010B1 (en)	1992-10-13	2002-06-25	Board Of Regents, The University Of Texas System	Recombinant P53 adenovirus compositions
US5747469A (en) *	1991-03-06	1998-05-05	Board Of Regents, The University Of Texas System	Methods and compositions comprising DNA damaging agents and p53
FR2717496B1 (fr) *	1994-03-18	1996-04-12	Rhone Poulenc Rorer Sa	Virus recombinants, préparation et utilisation en thérapie génique.
FR2705686B1 (fr) *	1993-05-28	1995-08-18	Transgene Sa	Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US6682728B1 (en) *	1993-10-13	2004-01-27	The United States Of America As Represented By The Department Of Health And Human Services	Efficient and selective adenoviral-mediated gene transfer into vascular neointima
EP1637608B1 (de) *	1993-10-25	2009-07-22	CANJI, Inc.	Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung
US6210939B1 (en) *	1993-10-25	2001-04-03	Canji, Inc.	Recombinant adenoviral vector and methods of use
TW442569B (en) *	1993-10-25	2001-06-23	Canji Inc	Recombinant adenoviral vector
FR2717495B1 (fr) *	1994-03-18	1996-04-12	Rhone Poulenc Rorer Sa	Virus recombinants, préparation et utilisation en thérapie génique.
FR2717497B1 (fr) *	1994-03-18	1996-04-12	Rhone Poulenc Rorer Sa	Virus recombinants, préparation et utilisation en thérapie génique.
US7252989B1 (en)	1994-04-04	2007-08-07	Board Of Regents, The University Of Texas System	Adenovirus supervector system
JP3816518B2 (ja)	1994-06-10	2006-08-30	ジェンベク、インコーポレイティッド	相補的なアデノウイルスベクター系と細胞系
FR2725213B1 (fr) *	1994-10-04	1996-11-08	Rhone Poulenc Rorer Sa	Vecteurs viraux et utilisation en therapie genique
FR2726285B1 (fr)	1994-10-28	1996-11-29	Centre Nat Rech Scient	Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
US6060238A (en) *	1995-02-13	2000-05-09	The Regents Of The University Of Michigan	Method and composition for regulating apoptosis
US6015665A (en) *	1995-02-13	2000-01-18	The Regents Of The University Of Michigan	Method and composition for regulating apoptosis
US7097972B1 (en)	1995-02-13	2006-08-29	Regents Of The University Of Michigan	Method and composition for regulating apoptosis
US5637456A (en) *	1995-02-17	1997-06-10	The University Of Texas, Board Of Regents	Rapid test for determining the amount of functionally inactive gene in a gene therapy vector preparation
FR2730637B1 (fr)	1995-02-17	1997-03-28	Rhone Poulenc Rorer Sa	Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
WO1996025507A2 (en) *	1995-02-17	1996-08-22	The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Methods of preparation and use of recombinant adenoviral vectors
US5707618A (en) *	1995-03-24	1998-01-13	Genzyme Corporation	Adenovirus vectors for gene therapy
US6747138B1 (en)	1995-04-03	2004-06-08	Regents Of The University Of Michigan	Methods and compositions for regulating Fas-associated apoptosis
US7807783B1 (en)	1995-04-03	2010-10-05	The Regents Of The University Of Michigan	Methods and compositions for regulating FAS-associated apoptosis
SI0833934T2 (sl)	1995-06-15	2013-04-30	Crucell Holland B.V.	Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji
US6783980B2 (en)	1995-06-15	2004-08-31	Crucell Holland B.V.	Packaging systems for human recombinant adenovirus to be used in gene therapy
US6482803B1 (en)	1995-09-01	2002-11-19	Board Of Regents, The University Of Texas System	Modification of mutated P53 gene in tumors by retroviral delivery of ribozyme A
US5863904A (en)	1995-09-26	1999-01-26	The University Of Michigan	Methods for treating cancers and restenosis with P21
US7087582B1 (en)	1995-09-26	2006-08-08	Regents Of The University Of Michigan	Combination for site-specifically transforming cells in vivo comprising a double-balloon catheter and nucleic acid comprising a gene encoding P21
US6054467A (en) *	1996-07-05	2000-04-25	Sidney Kimmel Cancer Center	Down-regulation of DNA repair to enhance sensitivity to P53-mediated apoptosis
US5958892A (en)	1996-07-30	1999-09-28	Board Of Regents, The University Of Texas System	2-methoxyestradiol-induced apoptosis in cancer cells
US6696423B1 (en)	1997-08-29	2004-02-24	Biogen, Inc.	Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
US6113913A (en)	1998-06-26	2000-09-05	Genvec, Inc.	Recombinant adenovirus
FR2790484B1 (fr)	1999-03-01	2003-01-03	Michel Marcel Andre Loiselet	Petrins malaxeurs fermenteurs, dotes de dispositifs novateurs en la matiere, pour le petrissage des pates visco-elastiques et la production de levain pateux
FR2829136B1 (fr)	2001-08-29	2006-11-17	Aventis Pharma Sa	Derives lipidiques d'aminoglycosides
US20030158112A1 (en)	2002-02-15	2003-08-21	Johns Hopkins University School Of Medicine	Selective induction of apoptosis to treat ocular disease
US8790664B2 (en)	2008-09-05	2014-07-29	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Multimodular assembly useful for intracellular delivery

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3534749B2 (ja) *	1991-08-20	2004-06-07	アメリカ合衆国	アデノウイルスが介在する胃腸管への遺伝子の輸送
FR2688514A1 (fr) *	1992-03-16	1993-09-17	Centre Nat Rech Scient	Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
GB9223084D0 (en) *	1992-11-04	1992-12-16	Imp Cancer Res Tech	Compounds to target cells

1993
- 1993-04-22 FR FR9304745A patent/FR2704234B1/fr not_active Expired - Lifetime
1994
- 1994-04-15 EP EP94913649A patent/EP0695360B1/de not_active Expired - Lifetime
- 1994-04-15 AU AU65721/94A patent/AU696245B2/en not_active Expired
- 1994-04-15 NZ NZ265306A patent/NZ265306A/en not_active IP Right Cessation
- 1994-04-15 WO PCT/FR1994/000421 patent/WO1994024297A1/fr not_active Ceased
- 1994-04-15 JP JP6522838A patent/JPH08508879A/ja active Pending
- 1994-04-15 ES ES94913649T patent/ES2264123T3/es not_active Expired - Lifetime
- 1994-04-15 PT PT94913649T patent/PT695360E/pt unknown
- 1994-04-15 EP EP06001083A patent/EP1652931A3/de not_active Withdrawn
- 1994-04-15 HU HU9503035A patent/HU220346B/hu unknown
- 1994-04-15 DE DE69434781T patent/DE69434781T2/de not_active Expired - Lifetime
- 1994-04-15 DK DK94913649T patent/DK0695360T3/da active
- 1994-04-15 AT AT94913649T patent/ATE332386T1/de active
- 1994-04-21 ZA ZA942778A patent/ZA942778B/xx unknown
1995
- 1995-10-17 NO NO19954132A patent/NO321454B1/no not_active IP Right Cessation
- 1995-10-18 FI FI954966A patent/FI118011B/fi not_active IP Right Cessation

Also Published As

Publication number	Publication date
AU696245B2 (en)	1998-09-03
NO954132L (no)	1995-10-17
HU9503035D0 (en)	1995-12-28
AU6572194A (en)	1994-11-08
HUT73464A (en)	1996-08-28
ES2264123T3 (es)	2006-12-16
DE69434781D1 (de)	2006-08-17
ZA942778B (en)	1995-01-09
ATE332386T1 (de)	2006-07-15
EP1652931A2 (de)	2006-05-03
FI118011B (fi)	2007-05-31
NO954132D0 (no)	1995-10-17
JPH08508879A (ja)	1996-09-24
FR2704234A1 (fr)	1994-10-28
FI954966A0 (fi)	1995-10-18
EP1652931A3 (de)	2006-05-17
FR2704234B1 (fr)	1995-07-21
WO1994024297A1 (fr)	1994-10-27
DE69434781T2 (de)	2007-06-14
NZ265306A (en)	1997-10-24
HU220346B (hu)	2001-12-28
DK0695360T3 (da)	2006-11-13
FI954966L (fi)	1995-10-18
PT695360E (pt)	2006-09-29
EP0695360B1 (de)	2006-07-05
EP0695360A1 (de)	1996-02-07

Legal Events

Date	Code	Title	Description
2014-04-28	MK1K	Patent expired

Publication	Publication Date	Title
NO321454B1 (no)	2006-05-15	Defektiv, rekombinant adenovirus inneholdende en heterolog DNA-sekvens hvis ekspresjon i en malcelle tillater i det minste partielt a inhibere celledeling, anvendelser og farmasoytisk preparat derav.
JP6375273B2 (ja)	2018-08-15	腫瘍選択的ｅ１ａおよびｅ１ｂ変異体
CA2836987C (en)	2016-07-05	Chimeric adenoviruses for use in cancer treatment
JP6566214B2 (ja)	2019-08-28	Ｒｅｉｃ遺伝子を発現する制限増殖型アデノウイルス
JPH08510122A (ja)	1996-10-29	動物起源のアデノウイルスベクターおよび遺伝子治療におけるそれらの使用
US20080292592A1 (en)	2008-11-27	Oncolytic Adenovirus Armed with Therapeutic Genes
JP2012139220A (ja)	2012-07-26	複製欠損アデノウイルスｔｎｆベクター
AU699867B2 (en)	1998-12-17	Recombinant adenoviruses for gene therapy in cancers
CN110295195A (zh)	2019-10-01	靶向肝癌的溶瘤腺病毒gd55-gsdme的构建和应用
SK282235B6 (sk)	2001-12-03	Lieková kombinácia na transfekciu a expresiu exogénov in vivo alebo ex vivo
JP2002335965A (ja)	2002-11-26	細胞特異的発現複製ベクター
US20220235332A1 (en)	2022-07-28	Fast and Accurate Three-Plasmid Oncolytic Adenovirus Recombinant Packaging System AD5MIXPLUS and Application Thereof
NO319893B1 (no)	2005-09-26	Defektiv, rekombinert adenovirus og farmasoytisk preparat omfattende denne.
US11951141B2 (en)	2024-04-09	Replication-enhanced oncolytic adenoviruses
CN1328372C (zh)	2007-07-25	肿瘤靶向基因－病毒zd55－il－24及其构建方法和应用
MXPA97002078A (en)	1997-06-01	Adenovirus that comprise two therapeutic genes: suicide and immunoestimula
JP7816735B2 (ja)	2026-02-18	腫瘍溶解性ウイルス及びそれを用いたがん治療
WO2007086631A1 (en)	2007-08-02	Recombinant adenoviruses capable of regulating angiogenesis
WO2008074189A1 (en)	2008-06-26	A recombinant adenovirus comprising recombinant khp50 gene and preparation method and uses thereof
JP2005530495A (ja)	2005-10-13	オールターナティブスプライシングされる核酸分子
JP7406263B2 (ja)	2023-12-27	改変アデノウイルス及びこれを含む医薬
JP2009513133A (ja)	2009-04-02	癌のウイルス療法のための条件複製ウイルス及び方法